An advisory committee for the Food and Drug Administration has narrowly voted to add six peptides to a drug compounding list.

An FDA panel is reviewing seven peptides for potential approval, sparking concerns about their widespread use in compounding pharmacies and the gray market.

U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry…